ReviewTherapeutic advances in endocrinology and metabolism2016
Metabolic consequences of modern immunosuppressive agents in solid organ transplantation.
Review in Therapeutic advances in endocrinology and metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03255265 (Microchimerism and cfDNA as Biomarkers for Acute Rejection After Organ Transplantation), which is not on this map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Microchimerism and cfDNA as Biomarkers for Acute Rejection After Organ Transplantation
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Pooled it
- Current Evidence on Dietary Factors and Kidney Allograft Function in Kidney Transplant Recipients: A Systematic Review.Current medicinal chemistry · 2024Pooled it
- Mortality risk factors of COVID-19 infection in kidney transplantation recipients: a systematic review and meta-analysis of cohorts and clinical registries.Scientific reports · 2021Pooled it
- Trial
- Post-transplant diabetes mellitus after kidney transplantation: pathogenesis, risk factors, and management strategies.Frontiers in endocrinology · 2026Review
- A Multi-National Survey on Immunosuppressive Regimens and Mycophenolate Monitoring Practices after Kidney Transplantation.Kidney & blood pressure research · 2026Article
- Rapid Corticosteroid Withdrawal After Cardiac Transplantation Improves Outcomes.Clinical transplantation · 2025Article
- New-Onset Diabetes After Transplantation in Renal Recipients: A Pilot Comparative Study of Immediate vs. Extended-Release Tacrolimus Formulation.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Obesity-associated Inflammation and Alloimmunity.Transplantation · 2025Review
- Changes in the gut microbiota and derived fecal metabolites may play a role in tacrolimus-induced diabetes in mice.Future microbiology · 2025Article
- New Onset Diabetes After Organ Transplantation: Risk Factors, Treatment, and Consequences.Diagnostics (Basel, Switzerland) · 2025Review
- Managing dyslipidemia in solid organ transplant patients.Indian heart journal · 2024Review
- Glycolysis Changes in Alloreactive Memory B Cells in Highly Sensitized Kidney Transplant Recipients Undergoing Desensitization Therapy.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Chronic kidney disease combined with metabolic syndrome is a non-negligible risk factor.Therapeutic advances in endocrinology and metabolism · 2024Review
- Rapid intestinal and systemic metabolic reprogramming in an immunosuppressed environment.BMC microbiology · 2023Article
- Rapid intestinal and systemic metabolic reprogramming in an immunosuppressed environment.Research square · 2023Article
- Longitudinal Epigenome-Wide Analysis of Kidney Transplant Recipients Pretransplant and Posttransplant.Kidney international reports · 2023Article
- 3D bioprinting of an implantable xeno-free vascularized human skin graft.Bioengineering & translational medicine · 2023Article
- Calcineurin inhibitors' impact on cardiovascular and renal function, a descriptive study in lung transplant recipients from the North of Spain.Scientific reports · 2022Review
- Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among other factors, sophistication of immunosuppressive (IS) regimen accounts for the remarkable success attained in the short- and medium-term solid organ transplant (SOT) survival. The use of steroids, mycophenolate mofetil and calcineurin inhibitors (CNI) have led to annual renal graft survival rates exceeding 90% in the last six decades. On the other hand, attrition rates of the allograft beyond the first year have remained unchanged. In addition, there is a persistent high cardiovascular (CV) mortality rate among transplant recipients with functioning grafts. These shortcomings are in part due to the metabolic effects of steroids, CNI and sirolimus (SRL), all of which are implicated in hypertension, new onset diabetes after transplant (NODAT), and dyslipidemia. In a bid to reduce the required amount of harmful maintenance agents, T-cell-depleting antibodies are increasingly used for induction therapy. The downsides to their use are greater incidence of opportunistic viral infections and malignancy. On the other hand, inadequate immunosuppression causes recurrent rejection episodes and therefore early-onset chronic allograft dysfunction. In addition to the adverse metabolic effects of the steroid rescue needed in these settings, the generated proinflammatory milieu may promote accelerated atherosclerotic disorders, thus setting up a vicious cycle. The recent availability of newer agent, belatacept holds a promise in reducing the incidence of metabolic disorders and hopefully its long-term CV consequences. Although therapeutic drug monitoring as applied to CNI may be helpful, pharmacodynamic tools are needed to promote a customized selection of IS agents that offer the most benefit to an individual without jeopardizing the allograft survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.